Synopsis
0
EU WC
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Neomycin
2. Neomycin Palmitate
3. Neomycin Sulfate
1. Neomycin Sulfate
2. 1405-10-3
3. Neomycin Trisulfate Hydrate
4. Akos016010116
Molecular Weight | 712.7 g/mol |
---|---|
Molecular Formula | C23H48N6O17S |
Hydrogen Bond Donor Count | 15 |
Hydrogen Bond Acceptor Count | 23 |
Rotatable Bond Count | 9 |
Exact Mass | 712.27966526 g/mol |
Monoisotopic Mass | 712.27966526 g/mol |
Topological Polar Surface Area | 436 Ų |
Heavy Atom Count | 47 |
Formal Charge | 0 |
Complexity | 953 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 18 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Neomycin sulfate |
Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
Active Ingredient | Neomycin sulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Oman Pharm Products; Teva; X Gen Pharms |
2 of 2 | |
---|---|
Drug Name | Neomycin sulfate |
Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
Active Ingredient | Neomycin sulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Oman Pharm Products; Teva; X Gen Pharms |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13615
Submission : 1998-09-01
Status : Inactive
Type : II
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-26
Pay. Date : 2013-02-13
DMF Number : 13378
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : R1-CEP 1999-184 - Rev 03
Issue Date : 2020-04-21
Type : Chemical
Substance Number : 197
Status : Valid
Registration Number : 217MF10976
Registrant's Address : 235 East 42nd Street, New York, NY 10017
Initial Date of Registration : 2005-11-14
Latest Date of Registration :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 124
Submission : 1953-07-23
Status : Inactive
Type : II
NDC Package Code : 0009-5238
Start Marketing Date : 2014-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Novartis Korea Ltd.
Registration Date : 2023-08-01
Registration Number : 20230801-211-J-1531
Manufacturer Name : Pharmacia & Upjohn Company LLC
Manufacturer Address : 7000 Portage Road, Kalamazoo, Michigan 49001, USA
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 262
Submission : 1940-01-01
Status : Inactive
Type : II
NDC Package Code : 0009-5238
Start Marketing Date : 2014-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 110
Submission : 1953-05-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 264
Submission : 1957-07-26
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13286
Submission : 1998-09-01
Status : Inactive
Type : II
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13615
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-26
Pay. Date : 2013-02-13
DMF Number : 13378
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 271
Submission : 1940-01-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 124
Submission : 1953-07-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 270
Submission : 1940-01-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 262
Submission : 1940-01-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 110
Submission : 1953-05-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13286
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 264
Submission : 1957-07-26
Status : Inactive
Type : II
Neomycin Sulfate, Micronised And Non-micronised
Certificate Number : R1-CEP 1999-184 - Rev 03
Status : Valid
Issue Date : 2020-04-21
Type : Chemical
Substance Number : 197
Certificate Number : R1-CEP 2017-006 - Rev 00
Status : Valid
Issue Date : 2023-04-13
Type : Chemical and TSE
Substance Number : 197
Certificate Number : R1-CEP 2001-317 - Rev 00
Status : Valid
Issue Date : 2010-09-07
Type : Chemical
Substance Number : 197
Certificate Number : R0-CEP 2022-013 - Rev 01
Status : Valid
Issue Date : 2023-02-15
Type : Chemical and TSE
Substance Number : 197
Certificate Number : R1-CEP 2011-029 - Rev 01
Status : Valid
Issue Date : 2020-02-27
Type : Chemical and TSE
Substance Number : 197
Registration Number : 217MF10976
Registrant's Address : 235 East 42nd Street, New York, NY 10017
Initial Date of Registration : 2005-11-14
Latest Date of Registration : 2022-06-22
Registration Number : 303MF10156
Registrant's Address : No. 8,Ziyang Road,Dianjun District,Yichang City,HubeiProvince,China
Initial Date of Registration : 2021-10-07
Latest Date of Registration : 2021-10-07
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : No
TE Code :
NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
Brand Name : POLY-PRED
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : EQ 0.35% BASE;10,000 UNITS/ML;0.5%
Approval Date : 1982-01-01
Application Number : 50081
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AT
NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : NEOMYCIN AND POLYMYXIN B SULFATE
Dosage Form : SOLUTION;IRRIGATION
Dosage Strength : EQ 40MG BASE/ML;200,000 UNITS/ML
Approval Date : 1986-04-08
Application Number : 62664
RX/OTC/DISCN : RX
RLD : No
TE Code : AT
RLD : No
TE Code :
BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE
Dosage Form : OINTMENT;TOPICAL
Dosage Strength : 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM
Approval Date : 1985-09-06
Application Number : 62381
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : NEOMYCIN SULFATE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 2016-06-10
Application Number : 204435
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
HYDROCORTISONE ACETATE; NEOMYCIN SULFATE
Brand Name : COR-OTICIN
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 1.5%;EQ 3.5MG BASE/ML
Approval Date : 1982-01-01
Application Number : 60188
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : NEOMYCIN SULFATE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 1982-01-01
Application Number : 60607
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : CORTISPORIN
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Approval Date : 1982-01-01
Application Number : 50169
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
METHYLPREDNISOLONE; NEOMYCIN SULFATE
Brand Name : NEO-MEDROL
Dosage Form : OINTMENT;OPHTHALMIC
Dosage Strength : 0.1%;EQ 3.5MG BASE/GM
Approval Date : 1982-01-01
Application Number : 60645
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE
Brand Name : NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
Dosage Form : CREAM;TOPICAL
Dosage Strength : EQ 3.5MG BASE/GM;0.1%
Approval Date : 1986-07-21
Application Number : 62595
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AT
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
Dosage Form : SOLUTION/DROPS;OTIC
Dosage Strength : 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Approval Date : 1983-08-25
Application Number : 62423
RX/OTC/DISCN : RX
RLD : No
TE Code : AT
Regulatory Info : Generic
Registration Country : Turkey
Dexamethasone; Neomycin Sulfate; Polymyxin B
Brand Name :
Dosage Form : EYE AND EAR DROPS
Dosage Strength : 1MG; 3.5MG; 6.000IU
Packaging : 5 Ml/Bottle
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey
Regulatory Info :
Registration Country : Italy
Brand Name : Halciderm Combi
Dosage Form :
Dosage Strength : Cream Derm 30 G 0,1 % + 0,37 %
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Dexamethasone Isonicotinate; Neomycin Sulfate
Brand Name : Desalfa
Dosage Form :
Dosage Strength : Gtt Orl 10 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Hydrocortisone; Polymyxin B; Neomycin Sulfate; Lidocaine
Brand Name : Mixotone
Dosage Form :
Dosage Strength : Gtt Oto 1Vial+ 1Vial Solv 10 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Parenteral
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Microlose (Lactose Monohydrate & Microcrystalline Cellulose) is used as a diluent in oral dosage forms such as tablets.
Pharmacopoeia Ref : DMF, EXCiPAT, KOSHER, HALAL, W...
Technical Specs : Lactose Monohydrate – 40%, Microcrystalline cellulose – 60%
Ingredient(s) : Lactose Monohydrate
Dosage Form : Softgels
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Starlose P40 (Starch & Lactose Monohydrate) is used as a diluent in oral dosage forms such as tablets.
Dosage Form : Gel
Grade : Parenteral, Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Application : Solubilizers
Excipient Details : Poloxamer 188 is used as a solubilizer, emulsifier, stabilizer in parenteral, OSDs & topical formulations such as creams, gels & lotions.
Pharmacopoeia Ref : ChP/USP/EP
Technical Specs : Oxyethylene unit: 75%-85%, Oxypropylene unit: 25%-30%
Ingredient(s) : Poloxamer 188
Dosage Form : Gel
Grade : Oral, Topical
Dosage Form : Cream / Lotion / Ointment
Grade : Parenteral, Oral, Topical
Dosage Form : Gel
Grade : Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Dosage Form : Emulsion
Grade : Oral, Topical
Dosage Form : Softgels
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Parenteral
Dosage Form : Injectable / Parenteral
Grade : Topical, Parenteral
Application : Co-Processed Excipients
Excipient Details : Presome ACD-1 is a mixture of HSPC/Cholesterol/MPEG2000-DSPE(3:1:1) that can greatly reduce the complexity of liposome production. It is used in parenteral dosage forms.
Pharmacopoeia Ref : NA
Technical Specs : Phospholipid/Cholesterol/MPEG2000-DSPE(3:1:1) Mixture
Ingredient(s) : Cholesterol Excipient
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
69
PharmaCompass offers a list of Neomycin Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Neomycin Sulfate manufacturer or Neomycin Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Neomycin Sulfate manufacturer or Neomycin Sulfate supplier.
PharmaCompass also assists you with knowing the Neomycin Sulfate API Price utilized in the formulation of products. Neomycin Sulfate API Price is not always fixed or binding as the Neomycin Sulfate Price is obtained through a variety of data sources. The Neomycin Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Neomycin Sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Neomycin Sulfate, including repackagers and relabelers. The FDA regulates Neomycin Sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Neomycin Sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Neomycin Sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Neomycin Sulfate supplier is an individual or a company that provides Neomycin Sulfate active pharmaceutical ingredient (API) or Neomycin Sulfate finished formulations upon request. The Neomycin Sulfate suppliers may include Neomycin Sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Neomycin Sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Neomycin Sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Neomycin Sulfate active pharmaceutical ingredient (API) in detail. Different forms of Neomycin Sulfate DMFs exist exist since differing nations have different regulations, such as Neomycin Sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Neomycin Sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Neomycin Sulfate USDMF includes data on Neomycin Sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Neomycin Sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Neomycin Sulfate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Neomycin Sulfate Drug Master File in Japan (Neomycin Sulfate JDMF) empowers Neomycin Sulfate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Neomycin Sulfate JDMF during the approval evaluation for pharmaceutical products. At the time of Neomycin Sulfate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Neomycin Sulfate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Neomycin Sulfate Drug Master File in Korea (Neomycin Sulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Neomycin Sulfate. The MFDS reviews the Neomycin Sulfate KDMF as part of the drug registration process and uses the information provided in the Neomycin Sulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Neomycin Sulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Neomycin Sulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Neomycin Sulfate suppliers with KDMF on PharmaCompass.
A Neomycin Sulfate CEP of the European Pharmacopoeia monograph is often referred to as a Neomycin Sulfate Certificate of Suitability (COS). The purpose of a Neomycin Sulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Neomycin Sulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Neomycin Sulfate to their clients by showing that a Neomycin Sulfate CEP has been issued for it. The manufacturer submits a Neomycin Sulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Neomycin Sulfate CEP holder for the record. Additionally, the data presented in the Neomycin Sulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Neomycin Sulfate DMF.
A Neomycin Sulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Neomycin Sulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Neomycin Sulfate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Neomycin Sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Neomycin Sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Neomycin Sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Neomycin Sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Neomycin Sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Neomycin Sulfate suppliers with NDC on PharmaCompass.
Neomycin Sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Neomycin Sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Neomycin Sulfate GMP manufacturer or Neomycin Sulfate GMP API supplier for your needs.
A Neomycin Sulfate CoA (Certificate of Analysis) is a formal document that attests to Neomycin Sulfate's compliance with Neomycin Sulfate specifications and serves as a tool for batch-level quality control.
Neomycin Sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Neomycin Sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Neomycin Sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Neomycin Sulfate EP), Neomycin Sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Neomycin Sulfate USP).